Linezolid Accord (Linezolid)

Linezolid Accord is an oxazolidinone antibiotic indicated for serious Gram‑positive infections. It is used in the following conditions:

• Methicillin‑resistant Staphylococcus aureus (MRSA) infections: provides bacterial eradication in complicated skin, soft‑tissue and bloodstream infections.
• Vancomycin‑resistant Enterococcus (VRE) infections: offers an effective alternative when vancomycin is ineffective.
• Community‑acquired and hospital‑acquired pneumonia: treats pneumonia caused by susceptible Gram‑positive pathogens.
• Skin and soft‑tissue infections: clears infection in cellulitis, abscesses and wound infections caused by resistant organisms.

• Linezolid binds to the 23S rRNA of the 50S ribosomal subunit, preventing formation of the initiation complex required for bacterial protein synthesis. This inhibition halts bacterial growth and leads to bacteriostatic activity against susceptible Gram‑positive organisms, including MRSA and VRE.

Linezolid may cause a range of adverse reactions. Monitoring patients for both common and serious events is recommended.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: loose stools, often self‑limited.
• Headache: transient cranial discomfort.
• Vomiting: occasional emesis.
• Rash: mild skin erythema or pruritus.
• Metallic taste: transient alteration of taste perception.

Serious or Rare Side Effects

• Myelosuppression: thrombocytopenia, anemia or neutropenia requiring laboratory monitoring.
• Peripheral neuropathy: sensory changes that may be irreversible.
• Serotonin syndrome: risk when combined with serotonergic agents.
• Lactic acidosis: rare metabolic disturbance.
• Severe hypotension: possible infusion‑related reaction.
• Anaphylaxis: rare but life‑threatening hypersensitivity.

Before initiating Linezolid Accord, clinicians should consider several safety measures.

• Renal impairment: assess kidney function and adjust therapy if needed.
• Hepatic impairment: monitor liver enzymes and consider dose modification.
• Hematologic monitoring: perform regular complete blood counts to detect myelosuppression.
• Drug interactions: avoid concomitant serotonergic drugs due to serotonin syndrome risk.
• Pregnancy and lactation: safety data are limited; weigh potential benefits against unknown risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Linezolid can interact with several drug classes, requiring vigilance.

Major Interactions (Avoid)

• Selective serotonin reuptake inhibitors (SSRIs) and other serotonergic agents: risk of serotonin syndrome.
• Monoamine oxidase inhibitors (MAOIs): may precipitate hypertensive crisis.
• Sympathomimetic agents (e.g., pseudoephedrine): can cause severe hypertension.

Moderate Interactions (Monitor Closely)

• Rifampin: induces metabolism, reducing linezolid exposure.
• Anticonvulsants such as phenytoin: may lower plasma concentrations.
• Warfarin: monitor INR as linezolid can affect anticoagulation control.